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In 2007, only 8% of the estimated 1 800 000 children 
(0 - 14 years) living with HIV in sub-Saharan Africa 
were receiving antiretroviral therapy (ART). Coverage 
will need to be expanded greatly if the goal of provid-
ing ART to 80% of children in need by 2010 is to be 
met.1 Moreover, recent evidence highlights early initia-
tion of ART as particularly critical for infants with HIV.2 
Clinical guidelines issued by the World Health Organi-
zation (WHO) now recommend immediate initiation of 
ART for all HIV-infected infants.3  
Paediatric ART management involves a complex proc-
ess of interactions between patients, families, health 
care providers and the antiretrovirals (ARVs) them-
selves. Barriers to the delivery of effective treatment 
occur both within the health care system and in the 
home. These include delayed diagnosis, limited avail-
ability of health care providers trained in paediatric 
ART, few available paediatric ARV formulations, com-
plicated regimens and dosing schedules, and poor pal-
atability of some ARVs. Difficulties in the home include 
overcrowding, difficult work schedules of the parents 
and the stresses associated with parental disclosure in 
the home. Unlike adults, children require changes in 
antiretroviral dose as they grow and become older, and 
rely upon adult caregivers to administer medicines.4  
Children have traditionally been dosed according to 
body surface area (BSA) (e.g. zidovudine (AZT), dida-
nosine (ddI), lopinavir/ritonavir (LPV/r)), weight (mg/kg) 
(e.g. stavudine (d4T), lamivudine (3TC), abacavir (ABC), 
nevirapine (NVP)) or dose per weight band (efavirenz 
(EFV)). Manufacturers’ recommendations for some ARV 
drugs (e.g. LPV/r) include both BSA and weight-based 
dosing methods.5 The calculation of BSA generally re-
quires accurate measurement of the child’s weight and 
length or height (ideally with a stadiometer or meas-
uring box), and a normogram or mathematical formu-
la (e.g. Mosteller formula).6 For both BSA and mg/kg 
weight-based dosing approaches, the calculated dose 
of each ARV drug must be rounded up or down as a 
‘best-fit’ dosage according to which solid or liquid for-
mulations of the ARV drug are available. This may lead 
to confusion and uncertainty on the part of the pre-
scriber. 
In resource-limited settings (RLS), primary care doctors 
and nurses rather than paediatricians are responsible 
for the majority of paediatric ART initiation and fol-
low-up. Lack of accurate measuring equipment and the 
relative complexity of BSA dosing may inhibit initiation 
of ART in infants and young children or mean that in-
appropriate doses are given. While the most ‘accurate’ 
dosing may be obtained with the use of liquid formula-
tions, large volumes of solutions (which may require 
refrigeration, e.g. d4T solution) may be challenging for 
caregivers to administer to young children, particularly 
if palatability is poor (e.g. LPV/r).
ART simplification strategies are required to help 
health care providers manage ART in children, and 
to help caregivers and children adhere to therapy. 
Interventions include the use of adult or preferably 
paediatric fixed-dose combinations (FDCs), selection 
of doses based on weight band rather than individual 
mg/kg or BSA doses, prescription of pills or capsules 
rather than liquids, and identification of reliable once-
daily regimens. 
Weight-band dosage tables assist health care providers 
by assigning a fixed dose of medication for a particular 
weight range (e.g. 1.5 ml of LPV/r solution for children 
weighing 4 - 9.9 kg, or half a 150 mg 3TC tablet for 
children weighing 14 - 19.9 kg). In large public sector 
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One of the obstacles to scaling up paediatric antiretroviral therapy (ART) coverage in resource-limited settings 
is the relative complexity of paediatric dosing. There is a need to simplify ART in order to facilitate treatment 
initiation and ongoing management of infants and children by health care providers, as well as to support 
adherence in the home. This article reviews the development of weight-band dosing tables as a strategy for 
simplifying the delivery of paediatric ART.
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treatment programmes, tables can reduce the time and 
risk of dosing errors involved in calculating multiple 
ARV doses by weight or BSA. They can also facilitate 
easier checking of doses against weight gain by cli-
nicians, nurses, pharmacists or adherence counsellors. 
Under-dosing of ARVs, due in part to a lack of regu-
lar dose adjustments for ongoing growth, has been 
described in a large cohort of children in the UK and 
Ireland.7 A study in Thailand found that 17 of 18 doc-
tors using a standardised drug dosage table avoided 
miscalculations and reported more confidence with 
prescriptions.8 
In 2006, the WHO published simplified weight-band 
dosing tables on all ARV drugs for which there were 
available paediatric indications, formulations or suf-
ficient information and evidence to provide guidance 
on prescribing and doses.9 Decisions about dosing were 
based upon manufacturers’ information, ARV formula-
tion choices, available data from clinical studies and 
expert paediatric pharmacology consultation. What 
was considered to be the ‘optimal’ dose for a particular 
weight band, given the limitations imposed by current-
ly available drug formulations, was selected. Weight-
band doses were determined by using BSA values 
calculated from median height-for-weight from inter-
national growth charts using the following formula: 
BSA = square root [[weight (kg) × height (cm)]/3 600]. 
The dosing tables are directed at RLS and are based on 
the following principles:
1.    It is preferable to use one formulation or fixed com-
bination of any given drug(s).
2.    Syringes or other standardised devices of various 
sizes should be available to support accurate dos-
ing of liquid formulations.
3.    Large volumes of liquid or syrup formulations should 
be avoided where possible.
4.    In general, children should be switched to available 
solid formulations as soon as possible or as soon as 
they are tolerated.
5.    If liquids or syrups are difficult because of storage, 
large volumes required or palatability, solid dosage 
formulations are preferable.
6.    If solid formulations of first-line and second-line 
drugs developed for children are unavailable, sol-
id formulations currently used for adults can be 
used.
7.    Many tablets, but not all, may be divided in half 
but not beyond as drug content cannot be guar-
anteed. Scored tablets are more easily split. Some 
tablets cannot be split, and the WHO recommends 
that where possible tablet splitting be done in the 
dispensing pharmacy using appropriate tablet cut-
ters.
8.    Some adult FDCs may result in under-dosing of 
individual components in children. This is of con-
cern, particularly with drugs such as NNRTIs and 
3TC where there is a low threshold for resistance. 
NVP requires a ‘lead-in’ dosage. During the first 2 
weeks, therefore rather use individual components 
of the regimen.
9.    Different dosing between a.m. and p.m. should be 
avoided where possible. However, in order to keep 
all regimens to no more than twice daily, there are 
instances where different quantities of solid dos-
age forms can be administered a.m. as opposed to 
p.m.
10.  The doses in the tables are presented in weight 
bands, accepting that some deviation from target 
dosing will occur.
11.  Children have to be weighed at each clinic visit, and 
dose changes are required as children grow and/or 
gain weight.
12.  When capsules are opened or tablets dissolved or 
crushed and added to food or liquid, it is important 
that the entire volume/amount of vehicle be taken 
to ensure administration of the full dose. 
The dosing tables are based on standardised weight 
bands starting from 5 kg body weight for the individual 
ARV drugs (excluding EFV, which starts from 10 kg) and 
10 - 14 kg for the fixed-dose combinations (AZT + 3TC, 
d4T + 3TC, AZT + 3TC + ABC, d4T + 3TC + NVP). The 
weight bands are in 1 kg divisions from 5 to 11 kg, and 
2 - 5 kg divisions from 12 to 35 or 40 kg.
Dosing tables may be adapted according to the spe-
cific drug formulations available to a regional or na-
tional treatment programme. For example, dual (d4T 
+ 3TC) or triple (d4T or AZT + 3TC + NVP) FDCs play 
an important role in paediatric ART in many countries 
(e.g. Thailand and many African countries), but are not 
widely used in South Africa. Satisfactory early clini-
cal and immunological outcomes have been described 
following the use of fractions of generic adult FDCs 
in children dosed according to a weight-band table 
method in Thailand.10 
In another project, a visual dosing aid (VDA) incorpo-
rating coloured dosing bands for five first-line ARV 
drugs was developed to assist clinicians in prescribing 
paediatric ART consisting of syrups, generic adult tab-
lets or a combination. It compared well with generic 
paediatric FDC tablets and could help facilitate paedi-
atric ART roll-out in RLS.11 
The South African national guidelines for the manage-
ment of HIV-infected children (2005) incorporate a 
weight-band dosing chart12,13 developed by the Cent-
ers for Disease Control and Prevention (CDC) and a 
number of international paediatric AIDS programmes 
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prior to the more widespread availability of FDCs. BSA 
dosing recommendations were converted to weight-
band doses using approximations of weight-for-age 
and height-for-age derived from standardised growth 
charts of girls from birth to 36 months and 20 years in 
the USA (National Center for Health Statistics). Dose 
for each weight band was based on the practicality of 
the available dosage forms for each drug, and practi-
cal storage and dosing instructions were included with 
the chart. The chart lacks dose recommendations for 
children weighing less than 5 - 7 kg and for HIV-TB 
co-infection.  
The Western Cape Antiretroviral Drug Dosing Chart for 
Children (2007), based on the 2006 WHO recommen-
dations, was developed by the author and colleagues as 
a pilot project for the HIV Directorate of the Western 
Cape (South Africa) provincial health department. The 
chart was directed at both clinicians and pharmacists 
involved in prescribing and dispensing ART for children, 
and it was successfully piloted at a number of HIV clin-
ics before being distributed across the province. It was 
produced as a laminated A4 colour copy. Standard 
first- and second-line ART regimens (including regi-
mens compatible with rifampicin-based TB treatment) 
as well as general comments relating to storage, ad-
ministration and common drug interactions and side-
effects of the individual ARV drugs were printed on the 
reverse side. Only ARV formulations available at public 
sector treatment facilities were included (no FDCs were 
available), and there was an emphasis on the early in-
troduction of solid formulations where possible. Frac-
tions of tablets (not less than half a tablet) were only 
incorporated for scored tablets. The target dose in mg/
kg or mg/m2 for each drug as well as the formula for 
calculating BSA was included to facilitate comparison 
of dosing methods when necessary. 
The following local practices were incorporated:
1.    The off-label ‘opened capsule’ d4T dosing method 
whereby a d4T capsule is opened and the pow-
der contents dispersed in a standardised volume 
of water and the required dose drawn up with a 
syringe and administered to the child (e.g. to ad-
minister a standardised d4T dose of 10 mg for the 
weight bands 7 - 9.9 kg, a 20 mg d4T capsule is 
opened and dispersed into 5 ml of water and 2.5 ml 
is withdrawn with a syringe and administered and 
the remaining 2.5 ml is discarded). The rationale 
for this method is to minimise the use of stavu-
dine solution (1 mg/ml when reconstituted), which 
is expensive, requires refrigeration, and results in 
relatively large medication volumes for administra-
tion to young infants at the usual dosing sched-
ule (1 mg/kg/dose). There are now data based on 
high-performance liquid chromatography analysis 
of active drug concentration in dispersed capsule 
solutions, supporting the accuracy of this method 
for certain brands of d4T capsules.14    
2.    Standardised doses of ritonavir used for pharmaco-
logical boosting of LPV/r (in order to achieve a ratio 
of 1:1) in children receiving concurrent LPV/r and 
rifampicin-based TB treatment.15 
3.    Colour coding of ARVs on the chart corresponding 
to colour coding methods used in the pharmacy for 
medication containers and syringes to assist par-
ents and caregivers with correct dosing. 
4.    The chart incorporated co-trimoxazole and multivi-
tamin syrup dosing according to weight bands.
5.    Since there were no standard weight-band dosing 
recommendations for infants weighing <5 kg in the 
WHO document (2006), it was recommended that 
a clinician experienced in ARV prescribing be con-
sulted for such cases. 
There are a number of approaches to validation of 
weight-band dosing.  Direct methods include pharma-
cokinetic (Pk) studies and therapeutic drug monitoring. 
Indirect methods include comparison of weight-based 
with BSA doses, and safety and efficacy studies. Quali-
tative studies assessing the usefulness of a weight-
band dosing table to prescribing clinicians and dis-
pensing pharmacists should be undertaken. 
Differing growth rates and the prevalence of malnutri-
tion could have a significant impact on the accuracy of 
weight-band dosing of drugs that are usually dosed by 
BSA. A study comparing the calculated BSA dose range 
with WHO weight-band doses for AZT, ddI, NVP and LPV/r 
using actual heights and weights of 601 children at 
the time of ARV initiation was undertaken at a terti-
ary hospital in South Africa in 2007.16 The median age 
was 28 months (interquartile range 13 - 62), 49% of 
children weighed <10 kg, and 59% and 63% of chil-
dren had weight-for-age and height-for-age z-scores 
<–2 (moderate to severe underweight or stunting), 
respectively. Children with body weight <5 kg were ex-
cluded as weight-based dosing recommendations were 
unavailable for this category, and children <6 months of 
age were excluded as LPV/r BSA dosing recommenda-
tions are different in this age group. The BSA dose rang-
es used were AZT 180 - 240 mg/m2, ddI 90 - 120 mg/m2, 
NVP 160 - 200 mg/m2, and L/r 230 - 300 mg/m2. 
Results are presented in Table I. The conclusion of this 
study was that the 2006 WHO simplified weight band-
dosing method effectively avoided under-dosing chil-
dren in relation to existing BSA dose recommendations 
for AZT, NVP and LPV/r suspensions. However, the au-
thors noted that the risk of over-dosing is greater with 
weight-band recommendations for existing capsule 
or tablet formulations of these ARVs. Further studies 
are recommended for the WHO weight-band dosing 
method. 
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         Weight-band dose relative to calculated BSA dose  
       range (N=601 children) (using anthropometric data  
ARV drug, BSA dose range,                         at time of starting ART)
formulations assessed Under-dosing (% of children) Over-dosing (% of children)
AZT
180 - 240 mg/m2                
Oral solution (10 mg/ml)                         2                       0.5 
Capsules (100 mg)                         8.5                      19
ddI
90 - 120 mg/m2
Tablets (25, 50, 100 mg, chewable or dispersable in water)                         0                      87
NVP
160 - 200 mg/m2
Oral suspension (10 mg/ml)                         0                      53
Tablets (200 mg)                         0                      61
Lopinavir/ritonavir
230 - 300 mg/m2
Oral solution (80/20 mg/ml)                        1.2                      26
Capsules (133.3/33.3 mg soft)                         0                      38
TaBlE i. WEiGHT-BanD DOSE RElaTiVE TO CalCUlaTED BODY SURFaCE aREa DOSE RanGE
A VDA to facilitate dosing calculations in response to 
children’s growth and weight during ARV treatment 
developed by Callens et al.11 was evaluated using an-
thropometric data from 55 children from the USA and 
324 children from the Democratic Republic of Congo 
(DRC). In comparison with WHO-recommended dosing, 
the authors noted a relative dosing difference of >20% 
in <3% of children for NVP, AZT and d4T but in 20% of 
children for 3TC, over-dosing being more frequent.11 
A detailed review of Pk studies and clinical outcome, 
safety and efficacy studies undertaken in children 
treated with individual or FDC ARV drugs dosed ac-
cording to weight bands is beyond the scope of this 
article. There are no reported Pk or clinical studies di-
rectly comparing weight band with mg/kg or BSA dos-
ing approaches.   
In July 2008, the WHO published a revised weight-
band dosing table for individual ARVs as well as dual 
and triple FDCs applicable to children >6 weeks of age, 
indicating the number of tablets or millilitres of so-
lution to be administered twice daily by weight band 
from 3 kg to 34.9 kg (Fig. 1).17 The table focuses on 
ARVs used in first-line regimens and was developed by 
the WHO Paediatric Antiretroviral Working Group us-
ing the 2006 WHO treatment recommendations, target 
doses and weight bands as a benchmark and reviewing 
currently available published and unpublished data to 
assess dosing. DdI is not included in the dosing table. 
Key supporting references are provided in the docu-
ment.18 See Table II for target doses or dosing ranges. 
A WHO generic tool was used to assess and evaluate 
the expected dose delivered of any product in relation 
to intended target doses. For all formulations, changes 
in the number of pills and switches from one formula-
tion to another occur at the same weight bands. There 
was an attempt to avoid dosing any single ARV com-
ponent below 90% of the intended delivered dose and 
not more than 25% above the intended dose (or dose 
range for products with an established dose range). For 
NVP, the aim was to avoid dosing below 100% of the 
minimum of the dose range (150 mg/m2). Discrepancies 
between dose delivered and intended dose were justi-
fied based on available Pk data, consideration of toxicity, 
and threshold for development of HIV drug resistance. 
Higher dosing for children who would fall into the lower 
weight bands (under 3 years) was accepted for drugs 
with known increased metabolism or clearance in the 
young child (NVP, 3TC, d4T, abacavir, LPV/r). 
In South Africa, the Antiretroviral Drug Dosing Chart 
(2009) is an update of the 2007 Western Cape version 
and incorporates elements of the WHO 2008 table; in 
particular, dosing recommendations for weight bands 
3 - 3.9 kg and 4 - 4.9 kg (Fig. 2). Many of the for-
mulations in the WHO table, in particular the FDCs, 
are not currently available to public sector treatment 
programmes in South Africa and so are excluded. The 
registration and availability of the paediatric strength 
heat-stable LPV/r tablet (Aluvia; 100 mg lopinavir/25 
mg ritonavir) is still awaited, but it has been included. 
Local dosing practices described in the 2007 chart have 
been retained with modification, e.g. the d4T opened-
capsule method is now used from 5 kg body weight. A 
comparative analysis of the revised weight band dosing 
in comparison with BSA dosing for AZT, NVP and L/r has 
been completed but not yet published. An analysis of 
the dose of LPV/r solution in mg/m2 that revised WHO 
weight band dose recommendations would provide, us-
ing anthropometric data on 976 children initiating ART 
at median age of 11.2 months, indicated doses con-
siderably in excess of 300/75 mg/m2, particularly for 
children <6 months of age.19 A protocol for an infant 
Pk study using the revised WHO weight-band dosing 
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table and incorporating safety and efficacy end-points 
has been developed. 
The use of weight-band ARV dosing approaches, adapt-
ed in accordance with locally available formulations 
and treatment programme conditions, is a key com-
ponent of simplifying paediatric ART for health care 
providers as well as children and their caregivers, and 
will contribute to expanding treatment coverage for 
HIV-infected infants and children.     
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Drug Target dosing range Considerations
ABC 8 - 10 mg/kg/dose twice daily  Clearance in children <3 years old is increased, but recent data 
on once-daily dosing in children from 3 months of age suggest 
favourable Pk profile
AZT 180 - 240 mg/m2 /dose twice daily  Twice-daily dosing is acceptable and preferred
   Dosing at the upper end of the range is recommended for central 
nervous system HIV disease; dosing at the lower end may be 
preferred in settings where anaemia is prevalent 
d4T 1 mg/kg/dose twice daily  Needed as a priority product despite well-recognised longer-term 
toxicities (lipodystrophy), as it is initially well tolerated, is safer 
to use in anaemia than AZT, and has lower laboratory monitoring 
requirements
   Avoid over-dosing wherever possible (noting recent revision to 
adult dosing recommendation to reduce dose) and especially for 
extended periods to minimise toxicity
ddI <3 months of age: 50 mg/m2/dose;  Enteric-coated formulations are preferred over the buffered form
 >3 months: 120 mg/m2/dose twice daily Needs to be given 1 hour before or 2 hours after food
  Once-daily dosing accepted over 6 years of age
3TC 4 mg/kg/dose twice daily  Clearance in children <3 years old is increased, and minimal 
observed toxicity allows for higher dosing in younger children (up 
to 5 mg/kg/dose twice daily)
NVP  A BSA dose range of 150 - 200 mg/m2/dose  Under-dosing must be avoided wherever possible owing to low 
twice daily is used to generate weight-band dosing barrier development of HIV drug resistance
   A reduced dose (150 - 200 mg/m2/dose once daily) is recom-
mended for the first 2 weeks when initiating NVP treatment 
regimens
   Young children require a higher NVP dose relative to the NRTI 
components than delivered in current adult FDCs
EFV By weight band (15 - 18.75 mg/kg/dose  Dosing not established for children <3 years 
 solid formulation or 19.5 mg/kg/dose suspension,  Suspension is over 30% less bio-available than solid formulations 
 once daily)  
LPV/rtv  Approved dose is 230/75.5 mg/m2/dose twice daily; Clearance in children <2 years is increased 
 300/75 mg/m2/dose is recommended in children Actual exposure depends on metabolism and inter-patient vari-
 <2 years of age, if taken with NNRTI, or for  ability, which is considerable 
 PI-experienced patients Heat-stable paediatric formulation recently approved (awaiting 
  registration in SA)
RTV Co-formulated with lopinavir (L:r ratio 4:1) Needed for use as a pharmacological booster with PI-based treat- 
 For patients receiving rifampicin, additional RTV ment and for children receiving rifampicin-based antituberculosis 
 dosed at 0.75 x L/r dose to achieve L:r ratio of 1:1 therapy
TaBlE ii. DOSinG COnSiDERaTiOnS FOR inDiViDUal anTiRETROViRal DRUGS inClUDED in THE REViSED WHO 
DOSinG TaBlE (2008) anD aDaPTED FOR THE anTiRETROViRal DRUG DOSinG CHaRT (2009)18 
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